nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—FPR1—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—bone cancer	0.00847	0.00913	CbGpPWpGaD
Nedocromil—FPR1—GPCR ligand binding—GRM4—bone cancer	0.00813	0.00877	CbGpPWpGaD
Nedocromil—PTGDR—GPCR ligand binding—GRM4—bone cancer	0.00785	0.00847	CbGpPWpGaD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—EIF2S1—bone cancer	0.00775	0.00836	CbGpPWpGaD
Nedocromil—CYSLTR1—G alpha (q) signalling events—GRM1—bone cancer	0.00734	0.00792	CbGpPWpGaD
Nedocromil—HSP90AA1—ErbB receptor signaling network—EGFR—bone cancer	0.00727	0.00785	CbGpPWpGaD
Nedocromil—FPR1—GPCR ligand binding—GRM1—bone cancer	0.00705	0.0076	CbGpPWpGaD
Nedocromil—CYSLTR2—G alpha (q) signalling events—GNA11—bone cancer	0.00682	0.00736	CbGpPWpGaD
Nedocromil—PTGDR—GPCR ligand binding—GRM1—bone cancer	0.0068	0.00734	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00656	0.00708	CbGpPWpGaD
Nedocromil—PTGDR—Thromboxane A2 receptor signaling—EGFR—bone cancer	0.0065	0.00701	CbGpPWpGaD
Nedocromil—HSP90AA1—Integrins in angiogenesis—TGFBR2—bone cancer	0.00628	0.00678	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR ligand binding—GRM4—bone cancer	0.00616	0.00664	CbGpPWpGaD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.0061	0.00658	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by constitutively active EGFR—EGFR—bone cancer	0.00602	0.0065	CbGpPWpGaD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—GNA11—bone cancer	0.00599	0.00646	CbGpPWpGaD
Nedocromil—HSP90AA1—Integrins in angiogenesis—IGF1R—bone cancer	0.00591	0.00638	CbGpPWpGaD
Nedocromil—CYSLTR2—Endothelins—JUN—bone cancer	0.0059	0.00637	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR ligand binding—GRM1—bone cancer	0.00534	0.00576	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—BMI1—bone cancer	0.00527	0.00569	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00509	0.0055	CbGpPWpGaD
Nedocromil—HSP90AA1—Hypoxic and oxygen homeostasis regulation of HIF-1-alpha—TP53—bone cancer	0.00506	0.00545	CbGpPWpGaD
Nedocromil—FPR1—GPCR ligand binding—SMO—bone cancer	0.00496	0.00536	CbGpPWpGaD
Nedocromil—PTGDR—GPCR ligand binding—SMO—bone cancer	0.00479	0.00517	CbGpPWpGaD
Nedocromil—CYSLTR1—G alpha (q) signalling events—GNA11—bone cancer	0.00473	0.0051	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—RGS1—bone cancer	0.00459	0.00495	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—GRM4—bone cancer	0.00459	0.00495	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—RGS1—bone cancer	0.00443	0.00478	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—GRM4—bone cancer	0.00443	0.00478	CbGpPWpGaD
Nedocromil—HSP90AA1—Semaphorin interactions—MET—bone cancer	0.00434	0.00468	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—GRM4—bone cancer	0.00427	0.0046	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00423	0.00456	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00419	0.00452	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—GRM4—bone cancer	0.00417	0.0045	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—RGS1—bone cancer	0.00417	0.0045	CbGpPWpGaD
Nedocromil—CYSLTR1—Endothelins—JUN—bone cancer	0.00409	0.00441	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—ZW10—bone cancer	0.00406	0.00438	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—GRM4—bone cancer	0.00403	0.00434	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—RGS1—bone cancer	0.00403	0.00434	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—GRM1—bone cancer	0.00398	0.0043	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.00388	0.00418	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—GRM1—bone cancer	0.00385	0.00415	CbGpPWpGaD
Nedocromil—HSP90AA1—Integrin-linked kinase signaling—JUN—bone cancer	0.00384	0.00415	CbGpPWpGaD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.0038	0.0041	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—bone cancer	0.00379	0.00409	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00378	0.00407	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR ligand binding—SMO—bone cancer	0.00376	0.00406	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—GRM1—bone cancer	0.0037	0.00399	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—ZW10—bone cancer	0.00363	0.00391	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—GRM1—bone cancer	0.00362	0.0039	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—GRM1—bone cancer	0.00349	0.00377	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—GRM4—bone cancer	0.00348	0.00375	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—RGS1—bone cancer	0.00348	0.00375	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of Androgen receptor activity—JUN—bone cancer	0.00337	0.00364	CbGpPWpGaD
Nedocromil—HSP90AA1—NRF2 pathway—GSTP1—bone cancer	0.00321	0.00346	CbGpPWpGaD
Nedocromil—HSP90AA1—NRF2 pathway—TGFBR2—bone cancer	0.00321	0.00346	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—GRM4—bone cancer	0.00316	0.00341	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—RGS1—bone cancer	0.00316	0.00341	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.00308	0.00332	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—GRM1—bone cancer	0.00302	0.00326	CbGpPWpGaD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—BRAF—bone cancer	0.00298	0.00321	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00297	0.0032	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00297	0.0032	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—RFC1—bone cancer	0.00279	0.00301	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of Telomerase—JUN—bone cancer	0.00276	0.00298	CbGpPWpGaD
Nedocromil—HSP90AA1—EPH-Ephrin signaling—MMP2—bone cancer	0.00276	0.00298	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TUBB4B—bone cancer	0.00275	0.00297	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—GRM1—bone cancer	0.00274	0.00296	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.00274	0.00295	CbGpPWpGaD
Nedocromil—HSP90AA1—LKB1 signaling events—TP53—bone cancer	0.00263	0.00284	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—SMO—bone cancer	0.00261	0.00281	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—GNA11—bone cancer	0.00257	0.00277	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—EZH2—bone cancer	0.00256	0.00277	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—SMO—bone cancer	0.00255	0.00275	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—RFC1—bone cancer	0.00249	0.00269	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—GNA11—bone cancer	0.00248	0.00267	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—GRM4—bone cancer	0.00246	0.00266	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—RGS1—bone cancer	0.00246	0.00266	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—SMO—bone cancer	0.00246	0.00265	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—GRM4—bone cancer	0.00241	0.0026	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—RGS1—bone cancer	0.00241	0.0026	CbGpPWpGaD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.00238	0.00257	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—GRM4—bone cancer	0.00238	0.00257	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—RGS1—bone cancer	0.00238	0.00257	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—JUN—bone cancer	0.00238	0.00256	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—GNA11—bone cancer	0.00233	0.00251	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—IL3—bone cancer	0.00233	0.00251	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—GNA11—bone cancer	0.00225	0.00243	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—IL3—bone cancer	0.00225	0.00242	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—RGS1—bone cancer	0.00219	0.00236	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—GRM4—bone cancer	0.00219	0.00236	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of Telomerase—EGFR—bone cancer	0.00217	0.00234	CbGpPWpGaD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—JUN—bone cancer	0.00217	0.00234	CbGpPWpGaD
Nedocromil—Pain—Carboplatin—bone cancer	0.00217	0.0297	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—GRM1—bone cancer	0.00214	0.0023	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—IL3—bone cancer	0.00211	0.00228	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—GRM1—bone cancer	0.00209	0.00226	CbGpPWpGaD
Nedocromil—HSP90AA1—EPH-Ephrin signaling—MMP9—bone cancer	0.00207	0.00224	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—GRM1—bone cancer	0.00206	0.00223	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—IL3—bone cancer	0.00204	0.0022	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—KIT—bone cancer	0.002	0.00216	CbGpPWpGaD
Nedocromil—Body temperature increased—Carboplatin—bone cancer	0.002	0.0274	CcSEcCtD
Nedocromil—HSP90AA1—Cellular responses to stress—GSTP1—bone cancer	0.002	0.00215	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NDUFA12—bone cancer	0.00197	0.00213	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—GNA11—bone cancer	0.00194	0.0021	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—SMO—bone cancer	0.00193	0.00208	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—GRM1—bone cancer	0.0019	0.00205	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—RGS1—bone cancer	0.00187	0.00201	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—GRM4—bone cancer	0.00187	0.00201	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—KIT—bone cancer	0.00184	0.00199	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—GNA11—bone cancer	0.00177	0.0019	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—IL3—bone cancer	0.00176	0.0019	CbGpPWpGaD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.00174	0.00187	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—DHFR—bone cancer	0.00173	0.00186	CbGpPWpGaD
Nedocromil—Nasal congestion—Cisplatin—bone cancer	0.00166	0.0227	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—NT5C3A—bone cancer	0.00163	0.00176	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—GRM1—bone cancer	0.00162	0.00175	CbGpPWpGaD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.00162	0.00174	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL3—bone cancer	0.0016	0.00173	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—MDM2—bone cancer	0.00158	0.0017	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.00157	0.00169	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—DHFR—bone cancer	0.00155	0.00167	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SMO—bone cancer	0.0015	0.00162	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SMO—bone cancer	0.00145	0.00157	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—MDM2—bone cancer	0.00145	0.00157	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CDK4—bone cancer	0.00145	0.00156	CbGpPWpGaD
Nedocromil—Rash erythematous—Epirubicin—bone cancer	0.0014	0.0191	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—GNA11—bone cancer	0.00138	0.00148	CbGpPWpGaD
Nedocromil—Otitis media—Epirubicin—bone cancer	0.00137	0.0188	CcSEcCtD
Nedocromil—Feeling hot—Epirubicin—bone cancer	0.00136	0.0187	CcSEcCtD
Nedocromil—CYSLTR1—GPCR downstream signaling—GNA11—bone cancer	0.00135	0.00145	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—SMO—bone cancer	0.00134	0.00144	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—GNA11—bone cancer	0.00133	0.00143	CbGpPWpGaD
Nedocromil—Stinging—Epirubicin—bone cancer	0.00132	0.0181	CcSEcCtD
Nedocromil—Dysphonia—Epirubicin—bone cancer	0.0013	0.0178	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—RGS1—bone cancer	0.00129	0.0014	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—GRM4—bone cancer	0.00129	0.0014	CbGpPWpGaD
Nedocromil—Rash erythematous—Doxorubicin—bone cancer	0.00129	0.0177	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—CHEK2—bone cancer	0.00129	0.00139	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—ATF1—bone cancer	0.00128	0.00138	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—ATF1—bone cancer	0.00128	0.00138	CbGpPWpGaD
Nedocromil—Otitis media—Doxorubicin—bone cancer	0.00127	0.0174	CcSEcCtD
Nedocromil—Feeling hot—Doxorubicin—bone cancer	0.00126	0.0173	CcSEcCtD
Nedocromil—HSP90AA1—Cellular responses to stress—RB1—bone cancer	0.00126	0.00136	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL3—bone cancer	0.00125	0.00135	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—ATF1—bone cancer	0.00124	0.00133	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—MET—bone cancer	0.00123	0.00133	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—GNA11—bone cancer	0.00122	0.00132	CbGpPWpGaD
Nedocromil—Stinging—Doxorubicin—bone cancer	0.00122	0.0167	CcSEcCtD
Nedocromil—CYSLTR1—GPCR downstream signaling—IL3—bone cancer	0.00122	0.00132	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL3—bone cancer	0.00121	0.0013	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.0012	0.0013	CbGpPWpGaD
Nedocromil—Dysphonia—Doxorubicin—bone cancer	0.0012	0.0165	CcSEcCtD
Nedocromil—Viral infection—Epirubicin—bone cancer	0.00118	0.0162	CcSEcCtD
Nedocromil—Cough increased—Epirubicin—bone cancer	0.00117	0.016	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—SMO—bone cancer	0.00114	0.00123	CbGpPWpGaD
Nedocromil—Conjunctivitis—Cisplatin—bone cancer	0.00113	0.0155	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—GRM1—bone cancer	0.00112	0.00121	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL3—bone cancer	0.00111	0.0012	CbGpPWpGaD
Nedocromil—Viral infection—Doxorubicin—bone cancer	0.0011	0.015	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—BRCA2—bone cancer	0.00109	0.00118	CbGpPWpGaD
Nedocromil—Cough increased—Doxorubicin—bone cancer	0.00108	0.0148	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by ERBB2—EGFR—bone cancer	0.00108	0.00116	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—MDM2—bone cancer	0.00107	0.00116	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFBR2—bone cancer	0.00107	0.00115	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—GNA11—bone cancer	0.00104	0.00113	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFBR2—bone cancer	0.00103	0.00111	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—MMP2—bone cancer	0.00103	0.00111	CbGpPWpGaD
Nedocromil—Visual impairment—Cisplatin—bone cancer	0.00101	0.0138	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—IGF1R—bone cancer	0.001	0.00108	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000992	0.00107	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ATF1—bone cancer	0.00097	0.00105	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IGF1R—bone cancer	0.00097	0.00105	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL3—bone cancer	0.000946	0.00102	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—JUN—bone cancer	0.000933	0.00101	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RGS1—bone cancer	0.000929	0.001	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GRM4—bone cancer	0.000929	0.001	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDK4—bone cancer	0.000908	0.00098	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MET—bone cancer	0.000877	0.000946	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CDK4—bone cancer	0.000877	0.000946	CbGpPWpGaD
Nedocromil—Eczema—Epirubicin—bone cancer	0.000864	0.0118	CcSEcCtD
Nedocromil—HSP90AA1—Disease—ENO2—bone cancer	0.000855	0.000922	CbGpPWpGaD
Nedocromil—Tremor—Cisplatin—bone cancer	0.000853	0.0117	CcSEcCtD
Nedocromil—Leukopenia—Cisplatin—bone cancer	0.000815	0.0112	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—CDK4—bone cancer	0.000812	0.000876	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFBR2—bone cancer	0.000809	0.000873	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GRM1—bone cancer	0.000805	0.000869	CbGpPWpGaD
Nedocromil—Eczema—Doxorubicin—bone cancer	0.0008	0.0109	CcSEcCtD
Nedocromil—HSP90AA1—Disease—DHFR—bone cancer	0.000793	0.000855	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SMO—bone cancer	0.00079	0.000853	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—RB1—bone cancer	0.00079	0.000852	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—MMP9—bone cancer	0.000771	0.000831	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IGF1R—bone cancer	0.000761	0.000821	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ATF1—bone cancer	0.000746	0.000805	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Cisplatin—bone cancer	0.000743	0.0102	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—MMP2—bone cancer	0.000732	0.000789	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KIT—bone cancer	0.000729	0.000787	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KIT—bone cancer	0.000728	0.000786	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL3—bone cancer	0.000728	0.000785	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—GNA11—bone cancer	0.000723	0.00078	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ENO2—bone cancer	0.000716	0.000772	CbGpPWpGaD
Nedocromil—Eosinophilia—Methotrexate—bone cancer	0.00071	0.00972	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—RB1—bone cancer	0.000706	0.000762	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KIT—bone cancer	0.000703	0.000759	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—BRAF—bone cancer	0.000684	0.000738	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ATF1—bone cancer	0.000672	0.000725	CbGpPWpGaD
Nedocromil—Influenza—Epirubicin—bone cancer	0.000671	0.00919	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Methotrexate—bone cancer	0.000667	0.00912	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—bone cancer	0.000665	0.00909	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—DHFR—bone cancer	0.000664	0.000716	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—EGFR—bone cancer	0.000663	0.000716	CbGpPWpGaD
Nedocromil—Dyspnoea—Cisplatin—bone cancer	0.000663	0.00907	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—BRAF—bone cancer	0.000661	0.000713	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL3—bone cancer	0.000655	0.000707	CbGpPWpGaD
Nedocromil—Bronchitis—Epirubicin—bone cancer	0.000646	0.00883	CcSEcCtD
Nedocromil—Pneumonia—Methotrexate—bone cancer	0.000643	0.0088	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Cisplatin—bone cancer	0.000642	0.00878	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—EGFR—bone cancer	0.000641	0.000691	CbGpPWpGaD
Nedocromil—Pain—Cisplatin—bone cancer	0.000636	0.0087	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—bone cancer	0.000624	0.00854	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—EGFR—bone cancer	0.000623	0.000672	CbGpPWpGaD
Nedocromil—Conjunctivitis—Methotrexate—bone cancer	0.000622	0.00851	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—bone cancer	0.000621	0.0085	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—GNA11—bone cancer	0.000621	0.00067	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—TP53—bone cancer	0.000616	0.000664	CbGpPWpGaD
Nedocromil—Eosinophilia—Doxorubicin—bone cancer	0.000615	0.00842	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—bone cancer	0.000602	0.00824	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—MDM2—bone cancer	0.000602	0.000649	CbGpPWpGaD
Nedocromil—Bronchitis—Doxorubicin—bone cancer	0.000597	0.00817	CcSEcCtD
Nedocromil—Body temperature increased—Cisplatin—bone cancer	0.000588	0.00804	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—bone cancer	0.000582	0.00796	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000577	0.0079	CcSEcCtD
Nedocromil—HSP90AA1—Disease—TGFBR2—bone cancer	0.000575	0.00062	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MDM2—bone cancer	0.000574	0.00062	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MDM2—bone cancer	0.000573	0.000619	CbGpPWpGaD
Nedocromil—Pharyngitis—Methotrexate—bone cancer	0.00057	0.0078	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—SMO—bone cancer	0.000567	0.000612	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP3A4—bone cancer	0.000563	0.000607	CbGpPWpGaD
Nedocromil—Sinusitis—Epirubicin—bone cancer	0.000562	0.00768	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—TGFBR2—bone cancer	0.000561	0.000605	CbGpPWpGaD
Nedocromil—Pneumonia—Doxorubicin—bone cancer	0.000557	0.00762	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—MDM2—bone cancer	0.000554	0.000598	CbGpPWpGaD
Nedocromil—Visual impairment—Methotrexate—bone cancer	0.000553	0.00757	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—KIT—bone cancer	0.000552	0.000595	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MMP9—bone cancer	0.00055	0.000593	CbGpPWpGaD
Nedocromil—Hypersensitivity—Cisplatin—bone cancer	0.000548	0.00749	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—bone cancer	0.000539	0.00737	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—bone cancer	0.000538	0.00737	CcSEcCtD
Nedocromil—Asthenia—Cisplatin—bone cancer	0.000533	0.0073	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—bone cancer	0.000533	0.0073	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1R—bone cancer	0.000527	0.000569	CbGpPWpGaD
Nedocromil—Sinusitis—Doxorubicin—bone cancer	0.00052	0.00711	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—GNA11—bone cancer	0.000519	0.00056	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—BRAF—bone cancer	0.000519	0.00056	CbGpPWpGaD
Nedocromil—Visual impairment—Epirubicin—bone cancer	0.000518	0.00709	CcSEcCtD
Nedocromil—Diarrhoea—Cisplatin—bone cancer	0.000509	0.00696	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—EGFR—bone cancer	0.000503	0.000542	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—JUN—bone cancer	0.000499	0.000538	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—JUN—bone cancer	0.000498	0.000538	CbGpPWpGaD
Nedocromil—Rhinitis—Doxorubicin—bone cancer	0.000498	0.00682	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—bone cancer	0.000493	0.00675	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—bone cancer	0.000489	0.0067	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—MMP9—bone cancer	0.000485	0.000523	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ATF1—bone cancer	0.000482	0.00052	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—JUN—bone cancer	0.000481	0.000519	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTP1—bone cancer	0.000481	0.000519	CbGpPWpGaD
Nedocromil—Visual impairment—Doxorubicin—bone cancer	0.000479	0.00656	CcSEcCtD
Nedocromil—Vomiting—Cisplatin—bone cancer	0.000473	0.00647	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—IL3—bone cancer	0.00047	0.000508	CbGpPWpGaD
Nedocromil—Rash—Cisplatin—bone cancer	0.000469	0.00641	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—MMP9—bone cancer	0.000468	0.000505	CbGpPWpGaD
Nedocromil—Dermatitis—Cisplatin—bone cancer	0.000468	0.00641	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—bone cancer	0.000458	0.00627	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—bone cancer	0.000447	0.00612	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—bone cancer	0.000444	0.000479	CbGpPWpGaD
Nedocromil—Nausea—Cisplatin—bone cancer	0.000442	0.00604	CcSEcCtD
Nedocromil—Cough—Methotrexate—bone cancer	0.000436	0.00597	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—MDM2—bone cancer	0.000435	0.000469	CbGpPWpGaD
Nedocromil—Chest pain—Methotrexate—bone cancer	0.000426	0.00582	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—KIT—bone cancer	0.000425	0.000458	CbGpPWpGaD
Nedocromil—Dysgeusia—Doxorubicin—bone cancer	0.000424	0.0058	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—bone cancer	0.000419	0.00573	CcSEcCtD
Nedocromil—Cough—Epirubicin—bone cancer	0.000408	0.00559	CcSEcCtD
Nedocromil—Anaphylactic shock—Methotrexate—bone cancer	0.000408	0.00558	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—TGFBR2—bone cancer	0.000402	0.000434	CbGpPWpGaD
Nedocromil—Chest pain—Epirubicin—bone cancer	0.000398	0.00545	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—bone cancer	0.000392	0.000423	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KIT—bone cancer	0.000392	0.000423	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—bone cancer	0.000392	0.000423	CbGpPWpGaD
Nedocromil—Dry mouth—Epirubicin—bone cancer	0.000389	0.00533	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—bone cancer	0.000387	0.0053	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—KIT—bone cancer	0.000383	0.000413	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Epirubicin—bone cancer	0.000382	0.00522	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1R—bone cancer	0.000379	0.000408	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—bone cancer	0.000379	0.000408	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—JUN—bone cancer	0.000378	0.000408	CbGpPWpGaD
Nedocromil—Cough—Doxorubicin—bone cancer	0.000378	0.00517	CcSEcCtD
Nedocromil—HSP90AA1—Disease—BRAF—bone cancer	0.000369	0.000398	CbGpPWpGaD
Nedocromil—Chest pain—Doxorubicin—bone cancer	0.000368	0.00504	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—bone cancer	0.000368	0.000397	CbGpPWpGaD
Nedocromil—Dyspnoea—Methotrexate—bone cancer	0.000364	0.00498	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—bone cancer	0.00036	0.00493	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—BRAF—bone cancer	0.00036	0.000388	CbGpPWpGaD
Nedocromil—Dyspepsia—Methotrexate—bone cancer	0.000359	0.00491	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—bone cancer	0.000353	0.00483	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Methotrexate—bone cancer	0.000352	0.00482	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—bone cancer	0.000352	0.00481	CcSEcCtD
Nedocromil—Pain—Methotrexate—bone cancer	0.000349	0.00477	CcSEcCtD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—bone cancer	0.000349	0.000376	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—bone cancer	0.000345	0.000373	CbGpPWpGaD
Nedocromil—Dyspnoea—Epirubicin—bone cancer	0.00034	0.00466	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—bone cancer	0.000336	0.0046	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—MDM2—bone cancer	0.000334	0.000361	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Methotrexate—bone cancer	0.000334	0.00456	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—bone cancer	0.00033	0.00451	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—bone cancer	0.000329	0.0045	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—TP53—bone cancer	0.000329	0.000355	CbGpPWpGaD
Nedocromil—Pain—Epirubicin—bone cancer	0.000326	0.00447	CcSEcCtD
Nedocromil—Urticaria—Methotrexate—bone cancer	0.000324	0.00443	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—bone cancer	0.000322	0.00441	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—bone cancer	0.000322	0.00441	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—TP53—bone cancer	0.000318	0.000343	CbGpPWpGaD
Nedocromil—Dyspnoea—Doxorubicin—bone cancer	0.000315	0.00431	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—bone cancer	0.000312	0.00427	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—bone cancer	0.000311	0.00425	CcSEcCtD
Nedocromil—HSP90AA1—Disease—MDM2—bone cancer	0.000309	0.000333	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000305	0.00417	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—bone cancer	0.000305	0.00417	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—bone cancer	0.000303	0.00415	CcSEcCtD
Nedocromil—Pain—Doxorubicin—bone cancer	0.000302	0.00413	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—bone cancer	0.000302	0.00413	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—bone cancer	0.000302	0.00413	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—MDM2—bone cancer	0.000301	0.000325	CbGpPWpGaD
Nedocromil—Hypersensitivity—Methotrexate—bone cancer	0.000301	0.00411	CcSEcCtD
Nedocromil—HSP90AA1—Disease—PTGS2—bone cancer	0.000298	0.000321	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—bone cancer	0.000297	0.00032	CbGpPWpGaD
Nedocromil—Asthenia—Methotrexate—bone cancer	0.000293	0.004	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—JUN—bone cancer	0.000291	0.000314	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Doxorubicin—bone cancer	0.000289	0.00395	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—bone cancer	0.000281	0.00385	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—bone cancer	0.000281	0.00384	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—bone cancer	0.000279	0.00382	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—bone cancer	0.000279	0.00382	CcSEcCtD
Nedocromil—Diarrhoea—Methotrexate—bone cancer	0.000279	0.00382	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—KIT—bone cancer	0.000275	0.000296	CbGpPWpGaD
Nedocromil—Asthenia—Epirubicin—bone cancer	0.000274	0.00375	CcSEcCtD
Nedocromil—Dizziness—Methotrexate—bone cancer	0.00027	0.00369	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—JUN—bone cancer	0.000262	0.000283	CbGpPWpGaD
Nedocromil—Diarrhoea—Epirubicin—bone cancer	0.000261	0.00357	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—bone cancer	0.00026	0.00356	CcSEcCtD
Nedocromil—Vomiting—Methotrexate—bone cancer	0.000259	0.00355	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—BRAF—bone cancer	0.000258	0.000278	CbGpPWpGaD
Nedocromil—Rash—Methotrexate—bone cancer	0.000257	0.00352	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—bone cancer	0.000257	0.00352	CcSEcCtD
Nedocromil—Headache—Methotrexate—bone cancer	0.000256	0.0035	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—bone cancer	0.000255	0.000275	CbGpPWpGaD
Nedocromil—Asthenia—Doxorubicin—bone cancer	0.000253	0.00347	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—bone cancer	0.000252	0.00345	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—bone cancer	0.000249	0.000269	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—bone cancer	0.000249	0.000269	CbGpPWpGaD
Nedocromil—Vomiting—Epirubicin—bone cancer	0.000243	0.00332	CcSEcCtD
Nedocromil—Nausea—Methotrexate—bone cancer	0.000242	0.00332	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—bone cancer	0.000242	0.00331	CcSEcCtD
Nedocromil—Rash—Epirubicin—bone cancer	0.000241	0.00329	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—bone cancer	0.00024	0.00329	CcSEcCtD
Nedocromil—Headache—Epirubicin—bone cancer	0.000239	0.00327	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—bone cancer	0.000234	0.0032	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—EGFR—bone cancer	0.000229	0.000247	CbGpPWpGaD
Nedocromil—Nausea—Epirubicin—bone cancer	0.000227	0.0031	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—bone cancer	0.000225	0.00307	CcSEcCtD
Nedocromil—Rash—Doxorubicin—bone cancer	0.000223	0.00305	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—bone cancer	0.000223	0.00304	CcSEcCtD
Nedocromil—Headache—Doxorubicin—bone cancer	0.000221	0.00303	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—MDM2—bone cancer	0.000216	0.000233	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—bone cancer	0.000211	0.000228	CbGpPWpGaD
Nedocromil—Nausea—Doxorubicin—bone cancer	0.00021	0.00287	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—bone cancer	0.000206	0.000222	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JUN—bone cancer	0.000188	0.000203	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—bone cancer	0.000183	0.000197	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—bone cancer	0.000173	0.000186	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—bone cancer	0.000148	0.000159	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—bone cancer	0.000124	0.000134	CbGpPWpGaD
